Boston Scientific Earns FDA Approval For Ranger Peripheral DCB
Executive Summary
The approval of the Ranger paclitaxel-coated balloon makes Boston Scientific the only company offering both a drug-eluting stent and drug-coated balloon for treating peripheral artery disease in the US.
You may also be interested in...
Boston Scientific Exceeds Wall Street’s Expectations In Q3
Boston Scientific’s management believes the ongoing recovery of procedure volumes and new technology will allow it to show revenue growth in the fourth quarter.
Boston Scientific Delivers Q2 Sales Growth Across Its Product Lines
Boston Scientific Corp. posted revenue gains across its varied product categories, helped by strong performance in emerging markets.
News We’re Watching: FDA Approves Medtronic's Affera, Roche's CGM Moves Closer To Approval, And More
Medtech Insight's News We're Watching covers medtech industry and research news you may have missed. This week, the Advanced Technologies and Treatments for Diabetes (ATTD) conference in Florence, Italy, included new results from studies of Roche's continuous glucose monitor and Medtronic's 780G insulin pump, Medtronic moved closer to earning FDA approval for its Affera ablation mapping and ablation system, and Linus Health expanded its technology for finding signs of cognitive problems in speech data.